COGZF Stock Chart & Stats
$2.40
-$0.24(-12.06%)
At close: 4:00 PM EDT
$2.40
-$0.24(-12.06%)
Day’s Range― - ―
52-Week Range$1.26 - $2.48
Previous CloseN/A
Volume3.00K
Average Volume (3M)183.00
Market Cap
$415.10M
Enterprise Value$434.77M
Total Cash (Recent Filing)$34.77M
Total Debt (Recent Filing)$359.02K
Price to Earnings (P/E)34.7
Beta0.17
Next Earnings
Feb 24, 2027EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend Yield1.76%
Share Statistics
EPS (TTM)0.07
Shares Outstanding172,126,420
10 Day Avg. Volume199
30 Day Avg. Volume183
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)8.01
Price to Sales (P/S)7.79
P/FCF Ratio50.90
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue7.42
Enterprise Value/Gross Profit22.01
Enterprise Value/Ebitda28.73
Forecast
1Y Price Target
$2.78Price Target Upside15.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.06
Revenue Forecast (FY)$52.99M
Bulls Say, Bears Say
Bulls Say
Contracted Revenue VisibilityThe expanded contracted revenue base provides meaningful forward visibility and supports continued growth over the next several quarters. A substantial portion is expected to convert in FY’27, reducing reliance on entirely new bookings while giving management a stronger foundation for planning investment and capacity.
Growing Clinical Trial ScaleRapid growth in new and active trials indicates increasing adoption of Cogstate’s assessments within clinical research workflows. Greater study scale can deepen customer relationships, expand recurring usage opportunities, and improve operating leverage as the company manages more trials on its technology platform.
Conservative Balance SheetMinimal leverage materially limits financial risk and preserves flexibility to fund product development, support customer delivery, return capital, or withstand periods of uneven operating performance. The expanding equity base and attractive recent returns also indicate that growth has been supported by a solid capital position.
Bears Say
Revenue And Margin VolatilityAlthough FY’26 profitability was strong, the history of uneven revenue and changing margins makes earnings less predictable than the current rebound might suggest. Margin variability can complicate forecasting and may limit the consistency of cash generation and operating leverage across future reporting periods.
Uneven Cash ConversionUneven conversion of reported profit into cash can reduce the funds available for reinvestment, dividends, or buybacks even when accounting earnings remain healthy. The recent decline in free cash flow and weaker operating cash coverage warrant monitoring because they may reflect timing or working-capital effects.
Channel Execution DependenceA substantial contribution from developing channel relationships increases dependence on partner execution for future bookings and customer access. Until these partnerships are fully established, changes in partner productivity or coordination could make sales conversion less predictable and affect the pace of contracted revenue growth.
Cogstate Ltd News
COGZF FAQ
What was Cogstate Ltd’s price range in the past 12 months?
Cogstate Ltd lowest stock price was $1.26 and its highest was $2.48 in the past 12 months.
What is Cogstate Ltd’s market cap?
Cogstate Ltd’s market cap is $415.10M.
When is Cogstate Ltd’s upcoming earnings report date?
Cogstate Ltd’s upcoming earnings report date is Feb 24, 2027 which is in 134 days.
How were Cogstate Ltd’s earnings last quarter?
Cogstate Ltd released its earnings results on Aug 17, 2026. The company reported $0.042 earnings per share for the quarter, beating the consensus estimate of $0.038 by $0.004.
Is Cogstate Ltd overvalued?
According to Wall Street analysts Cogstate Ltd’s price is currently Undervalued.
Does Cogstate Ltd pay dividends?
Cogstate Ltd pays a Annually dividend of $0.029 which represents an annual dividend yield of 1.76%. See more information on Cogstate Ltd dividends here
What is Cogstate Ltd’s EPS estimate?
Cogstate Ltd’s EPS estimate is 0.04.
How many shares outstanding does Cogstate Ltd have?
Cogstate Ltd has 172,126,420 shares outstanding.
What happened to Cogstate Ltd’s price movement after its last earnings report?
Cogstate Ltd reported an EPS of $0.042 in its last earnings report, beating expectations of $0.038. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cogstate Ltd?
Currently, no hedge funds are holding shares in COGZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogstate Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.78 (15.73% Upside)
$2.78 (15.73% Upside)
Blogger Sentiment
Bullish
COGZF Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.47%
12-Months-Change
Fundamentals
Return on Equity
21.61%
Trailing 12-Months
Asset Growth
20.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cogstate Ltd
Melbourne, Australia-based Cogstate Limited, established in 1999, is a neuroscience technology company specializing in computerized cognitive assessments and digital solutions for clinical outcome evaluations. Its comprehensive suite of cognitive services includes project and data management, scientific consulting, statistical analysis, procurement of assessment scales, rater training, and monitoring solutions. The company operates through two distinct divisions. The Clinical Trials segment delivers technology and support services designed to measure the impact of diseases, pharmaceuticals, medical devices, or other interventions on human participants in clinical studies, primarily serving pharmaceutical and biotechnology clients. Concurrently, its Healthcare segment offers Cognigram, a system facilitating regular and standardized testing to assist primary care physicians and hospitals in the early identification of cognitive decline. By June 30, 2022, Cogstate had participated in an estimated 1,800 academic research initiatives.
COGZF Company Deck
COGZF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong, diversified top-line growth, record sales and a materially expanded contracted revenue base, backed by improving second-half margins and completed AI products—positioning the business for continued growth. Management acknowledged near-term margin pressure from purposeful capability investments, conversion timing risk for contracted revenue, a small FX tailwind that may not recur, and dependence on nascent channel partnerships. On balance, the positive operational momentum, robust pipeline and clear technology roadmap outweigh the manageable short-term risks.View all COGZF earnings summariesCOGZF Stock 12 Month Forecast
Average Price Target
$2.78
▲(15.73% Upside)
Technical Analysis
Tali Digital
―
Opyl Ltd.
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
PainChek Ltd
―
Ownership Overview
3.73% Insiders
0.47% Mutual Funds
<0.01% Other Institutional Investors
95.78% Public Companies and
Individual Investors